EULAR 2025 promotes a “hit hard and early” treat-to-target strategy in high-risk psoriatic arthritis (PsA) among other immunology indications, using frequent assessment and rapid therapy escalation to achieve remission or low disease activity. In Europe this strategy is enabled by a wide range of approved biologic and targeted synthetic DMARDs acting on TNF, IL17, IL23, JAK, and TYK2, with more TYK2 inhibitors and IL17focused agents in late-stage development. For Insights Corner we particularly focused on PsA although the EULAR focused on all the immunology indications including rare and orphans